Company profile
Gilead Sciences, Inc.
Pipeline19 assets
- LenacapavirHIV capsid inhibitor / Long-acting injectable / VirologyHIV Prevention (PrEP, PURPOSE 365)Phase 3HIV Treatment (in combinations)Phase 3HIV Treatment (with bNAbs)Phase 2
- Bictegravir/lenacapavir oral combinationINSTI + capsid inhibitor / Oral / VirologyHIV Treatment (virologically suppressed, ARTISTRY-1 & ARTISTRY-2)Phase 3
- Islatravir/lenacapavir oral combinationLong-acting oral / VirologyHIV Treatment (virologically suppressed, ISLEND-1 & ISLEND-2)Phase 3
- Lenacapavir + teropavimab + zinlirvimabCapsid + bNAbs / Long-acting injectable / VirologyHIV Treatment (virologically suppressed)Phase 2
- GS-1720/GS-4182GS-1720/GS-4182 / INSTI/capsid inhibitor / Long-acting oral / VirologyHIV Treatment (WONDERS-1 & -2)Phase 2
- Teropavimab + zinlirvimabbNAbs / Broadly neutralizing antibodies / VirologyHIV CurePhase 2
- VesatolimodVirologyHIV Cure (FRESH)Phase 2
- SelgantolimodVirologyHBV CurePhase 2
- HepcludexHepcludex / VirologyChronic HDV with compensated liver disease (MYR301)FiledBLA pending (US); Approved (EU)USEU
- EdecesertibInflammationLupus (COSMIC)Phase 2
- Tilpisertib fosmecarbilInflammationInflammatory bowel disease (PALEKONA)Phase 2
- α4β7 inhibitorα4β7 / InflammationInflammatory Bowel Disease (SWIFT)Phase 2
- Sacituzumab govitecan-hziyAntibody-drug conjugate / Oncology1L metastatic triple-negative breast cancer (PD-L1-, ASCENT-03)FiledsBLA pendingUS1L metastatic triple-negative breast cancer (PD-L1+, with pembrolizumab, ASCENT-04)FiledsBLA pendingUSHigh risk adjuvant triple-negative breast cancer (with pembrolizumab, ASCENT-05)Phase 3
- Axicabtagene ciloleucelCD19 CAR / Cell therapy / Oncology2L+ high-risk follicular lymphoma (ZUMA-22)Phase 31L high-risk large B-cell lymphoma (ZUMA-23)Phase 3
- Brexucabtagene autoleucelCD19 CAR / Cell therapy / OncologyPediatric acute lymphocytic leukemia/non-Hodgkin lymphoma (ZUMA-4)Phase 2
- Anitocabtagene autoleucelCell therapy / Oncology2-4L relapsed/refractory multiple myeloma (iMMagine-3)Phase 34L+ relapsed/refractory multiple myeloma (iMMagine-1)FiledBLA pendingUS
- KITE-363KITE-363 / CD19/CD20 bicistronic / Cell therapy / OncologyRelapsed/refractory diffuse large B-cell lymphomaPhase 1RMAT designationRheumatology (autoimmune)Phase 1
- DenikitugGS-1811 / OncologyAdvanced cancersPhase 1
- Domvanalimab + zimberelimabAnti-TIGIT + anti-PD1 / Combination therapy / Oncology1L metastatic non-small cell lung cancer (with chemo, STAR-121)Phase 31L head and neck squamous cell carcinoma (VELOCITY-HNSCC)Phase 2